DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?

导出 LinkOut

翻译打印收藏纠错

第一作者： Inés,Valencia

第一单位： Vascular Pharmacology and Metabolism Group (FARMAVASM), Department of Pharmacology, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.

作者： Inés,Valencia ^[1] ; Concepción,Peiró ^[2] ; Óscar,Lorenzo ^[1] ; Carlos F,Sánchez-Ferrer ^[2] ; Jürgen,Eckel ^[3] ; Tania,Romacho ^[4]

作者单位： Vascular Pharmacology and Metabolism Group (FARMAVASM), Department of Pharmacology, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain. ^[1] Instituto de Investigaciones Sanitarias del Hospital Universitario La Paz (IdiPAZ), Madrid, Spain. ^[2] Laboratory of Vascular Pathology and Diabetes, FIIS-Fundación Jiménez Díaz, Universidad Autónoma Madrid, Madrid, Spain. ^[3] Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM) Network, Madrid, Spain. ^[4] German Diabetes Center, Institute for Clinical Diabetology, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany. ^[5]

关键词 ACEi COVID-19 SARS-CoV-2 angiotensin converting enzyme 2 cardiovascular disease diabetes dipeptidyl peptidase 4 gliptins

DOI 10.3389/fphar.2020.01161

PMID 32848769

发布时间 2020-09-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in pharmacology

2020年11卷

1161页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除